Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Leukemia. 2018 Jun;32(6):1414-1420. doi: 10.1038/s41375-018-0099-8. Epub 2018 Mar 21.
Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.
孤立性浆细胞瘤是一种罕见的浆细胞疾病,可能表现为单个骨病变(P 骨)或髓外浆细胞瘤(P-EM)。目前缺乏对浆细胞瘤的预后因素和结局进行大样本分析的研究。虽然放射治疗(RT)是首选治疗方法,但缺乏评估最佳 RT 剂量的数据。在这项研究中,我们利用 2000 年至 2011 年国家癌症数据库中的浆细胞瘤数据来回答这些问题。共有 5056 名患者纳入研究(中位年龄 62 岁;范围 52-72 岁)。为了获得纯浆细胞瘤队列,将潜在的多发性骨髓瘤患者排除在研究之外(骨髓受累、全身化疗使用)。P 骨构成了 70%的患者。P-EM 的中位总生存期(OS)明显长于 P 骨(132 与 85 个月),而软组织/结缔组织的 OS 则差于 P-EM 的其余部分(82 与 148 个月)。多变量分析显示,与 OS 较差相关的因素包括年龄较大(≥65 岁)、存在 P 骨和接受剂量<40Gy 的放疗。